Ivacaftor: a novel mutation modulating drug

Cystic fibrosis (CF) is multisystemic disorder presenting in newborn period to adulthood, predominantly affecting respiratory system. It is caused by mutation in CF transmembrane conductance regulator gene. ΔF508 is the most common mutation seen worldwide. Supportive management with bronchodilators,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and diagnostic research 2014-11, Vol.8 (11), p.SE01-SE05
Main Authors: Kapoor, Harit, Koolwal, Astha, Singh, Ankur
Format: Article
Language:English
Subjects:
cystic fibrosis
Genetics Section
ivacaftor
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cystic fibrosis (CF) is multisystemic disorder presenting in newborn period to adulthood, predominantly affecting respiratory system. It is caused by mutation in CF transmembrane conductance regulator gene. ΔF508 is the most common mutation seen worldwide. Supportive management with bronchodilators, anti-inflammatory, mucolytics, antibiotics are the corner stone of therapy. Mutation specific drug, Ivacaftor, was recently approved USFDA in January 2012 for patients carrying G551D mutation. It is approved in patients who are six years and older in 150 mg twice daily dosing schedule with fat containing meals. It improves the lung function and other aspects of disease including weight gain. The side effects like upper respiratory infection, headache, rash, diarrhoea, stomach ache and dizziness are mild and self-limiting. This is excellent example of promise of personalised medicine - targeted drug that treat patients with specific genetic makeup.
ISSN:2249-782X
0973-709X
DOI:10.7860/JCDR/2014/6486.5158